CDDO-EA

• CAT Number: I005536
• CAS Number: 932730-51-3
• Molecular Formula: C33H46N2O3
• Molecular Weight: 518.73
• Purity: ≥95%
• Target: KEAP1-Nrf2
• Solubility: 10 mM in DMSO
• Storage: Store at -20℃
• IUPAC Name: (4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-N-ethyl-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxamide
• InChI: InChI=1S/C33H46N2O3/c1-9-35-27(38)33-14-12-28(2,3)18-21(33)25-22(36)16-24-30(6)17-20(19-34)26(37)29(4,5)23(30)10-11-31(24,7)32(25,8)13-15-33/h16-17,21,23,25H,9-15,18H2,1-8H3,(H,35,38)/t21-,23-,25-,30-,31+,32+,33-/m0/s1
• InChIKey: RZRQJICXYQPEQJ-YKEYHJQHSA-N
• SMILES: CCNC(=O)[C@@]12CC[C@@]3([C@@H]([C@@H]1CC(CC2)(C)C)C(=O)C=C4[C@]3(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)C

CDDO-EA (Cat.No:I005536), also known as bardoxolone methyl, is a synthetic triterpenoid compound with anti-inflammatory, antioxidant, and anticancer properties. It activates Nrf2, a transcription factor that regulates cellular defense against oxidative stress, inflammation, and carcinogenesis. CDDO-EA has shown promising results in preclinical studies as a potential therapy for various diseases, including cancer, chronic kidney disease, and pulmonary fibrosis. Clinical trials are ongoing to evaluate its safety and efficacy in humans.

Reference

[1]. Liby K, et al. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res. 2007 Mar 15;67(6):2414-9.


[2]. Suh N, et al. Synthetic triterpenoids, CDDO-Imidazolide and CDDO-Ethyl amide, induce chondrogenesis. Osteoarthritis Cartilage. 2012 May;20(5):446-50.